Magnesium L-Threonate Vertical: Slutsky 2010 BBB Research, the One Human RCT, the Patient-Experience Timeline, the Patent Funding Conflict, and the Buyer Guide for Closing the 6--20x Magtein Standardization Gap

The evidence problem: one human RCT, n=44, Magceutics-funded

The entire clinical evidence base for Magnesium L-threonate is a single human RCT. Slutsky et al. (2010, Neuron) demonstrated elevated cerebrospinal-fluid magnesium in rats — the result that drives the "uniquely crosses the blood-brain barrier" marketing claim. But there is no published human CSF study replicating that enhancement. The human RCT (Liu et al., 2016, Biogerontology) enrolled 44 adults across 12 weeks at ~1.5–2 g/day elemental magnesium as the L-threonate salt, with a composite cognitive-battery endpoint and modest cognitive-age reduction in the active arm. The RCT was funded by Magceutics — the entity that holds the MIT-licensed Magtein® trademark and the royalty stream. No independent replication exists.

The lived-experience timeline: week 1, week 4, week 8

The three lens articles capture three readable shapes of Magnesium. The studies article is the mechanism and the n=44 ceiling. The patient-experience article (lens = anecdata, semantically "patient-experience") maps ~200 reader emails plus r/Nootropics, r/Supplements, and r/Fitness thread signal onto a week-by-week timeline across sleep, anxiety, and muscle cramps. Sleep effects arrive in week one (vivid dreams, faster onset) and stabilize by week four. Muscle-cramps resolution is the cleanest signal, contingent on pre-supplementation cramp history. Anxiety splits cleanly by week eight — residual calm in the deficient, null finding in the replete. The uncertainty article covers the Slutsky-2010 rat-to-human CSF translation gap, the Magceutics funding conflict, the BBB-crossing extrapolation, and the regression-to-the-mean ceiling on subjective cognition endpoints.

The buyer-guide hinge: verifying Magtein® vs closing the 6–20× gap

Most retail "magnesium threonate" bottles are not the same intervention as the Liu 2016 trial material. The L-threonate salt is ~8–10% elemental by weight; the Liu 2016 trial dose of 1.5–2 g/day elemental magnesium translates to roughly 15–25 g/day of the L-threonate salt. A typical 500 mg front-of-bottle capsule without an elemental-mg column on Supplement Facts sits 6–20× under the trial dose — with no Magceinics/NBTY/MIT license disclosure and no Magtein® trademark. The buyer guide walks through the elemental-vs-compound weight distinction, marker-by-marker comparison of L-threonate vs glycinate/citrate/oxide, the five-point brand filter (Magtein® on label / CoA dated / elemental Mg / MIT-license provenance / USP+NSF+ConsumerLab), and the cheap-bottle warning.

Why this is a recurring vertical

Every Tier 3 topic whose lens trio studies / anecdata / uncertainty + 1 buyer guide completes now gets promoted to a recurring vertical at /verticals/<topic-slug>. Black Seed Oil was wedge 1, Probiotics was wedge 2, Magnesium L-threonate is the third. The vertical surfaces the four pages together so the reader can move from "what does the evidence say" through "what does it feel like" and "what isn't the evidence showing" to "what should I actually buy" without re-orienting between tabs.